# Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients

> **NCT04439955** · PHASE2 · COMPLETED · sponsor: **Stero Biotechs Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** CBD

## Key facts

- **NCT ID:** NCT04439955
- **Lead sponsor:** Stero Biotechs Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-02-01
- **Primary completion:** 2021-07-30
- **Final completion:** 2021-07-30
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2024-04-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04439955

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04439955, "Study to Evaluate the Safety, Tolerability and Efficacy of Cannabidiol (CBD) as a Steroid-sparing Therapy in Chronic Spontaneous Urticaria (CSU) Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04439955. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*